

SUBJECT INDEX VOLUME 26

A

Acetylcholine release, 325
Acetylcholine, 583
ACTH, 94, 358, 574, 672, 778
Adaptive behavior change, 520
Addiction, 1, 164, 703
Adenosine, 422
Adherence, 817
 α_2 -adrenoceptor, 468
Adrenocorticotropin, 286
Adrenocorticotropin, 106
Affective disorder, 368
Age of onset, 237
Aggression, 431, 660
Aging, 468, 672
Agitation, 494
Alcohol dependence, 115
Alcohol, 27, 479
Alcohol-nonpreferring rats, 191
Alcohol-preferring rats, 191
Allelic association, 115
Amitriptyline, 565
Amphetamine, 64, 311, 286, 295, 765
Anorexia nervosa, 789
Antagonist, 574
Antidepressant drugs, 605
Antidepressants, 246, 368, 615
Antipsychotics, 204, 583, 817
Antisense oligonucleotide, 259
Anxiety, 94
Anxiolysis, 729
Apoptosis, 397
Association study, 489
Association, 692
Atrophy, 229
Attention deficit hyperactivity disorder (ADHD), 625, 716
Attention, 27, 802
Atypical antipsychotic drugs, 456
Atypical features, 237
AVP, 672

B

Basal ganglia, 164
Bax, 397
Behavior, 64, 191, 431
Behavioral sensitization, 1, 18
Bipolar disorder, 415, 530
Bipolar illness, 216
Brain banks, 143
Brain imaging, 376
Brain, 86, 802
(+)BW373U86, 744

C

C57Bl/6 mouse, 444s
Caffeine, 27, 422
Cannabis, 479
CDNA array, 415

Central chemoreflex, 824
Cerebral blood flow, 802
Cerebral glucose metabolism, 376
c-Fos mRNA, 301
c-Fos, 259
Challenge test, 653
Cholecystokinin-B receptor, 824
Cholecystokinin-tetrapeptide (CCK-4), 824
Cholinergic, 672
Cigarette smoking, 75
Cingulate, 275
Clinical diagnosis, 143
Clomipramine, 653
Clozapine, 583, 765
Cluster analysis, 530
Cocaine, 18, 130, 376, 422, 444, 479
Cognition, 27, 176, 183, 505, 802
Cognitive task, 682
Cognitive, 376
Compliance, 817
Conditioned place preference, 130, 444
Conditioning, 703
Context, 703
Corticosterone, 286
Corticotropin releasing factor, 574
Corticotropin-releasing hormone, 94
Cortisol, 106, 358, 505, 672, 778
Course of illness, 237
Craving, 376
CREB, 605
Cytokine, 86, 204

D

D-Amphetamine, 595
Delta opioid receptor, 744
Delusional disorder, 794
Dementia, 494
Depression, 94, 237, 358, 643, 653, 744
Desipramine, 653
Development, 625
d-fenfluramine, 340
Diphenhydramine, 27
Dizocilpine, 456
dl-Fenfluramine, 269
DNA microarray, 634
Dopamine D1 receptor, 737
Dopamine D2 receptors, 18, 737
Dopamine D4 receptors, 625
Dopamine psychosis, 794
Dopamine release, 311
Dopamine reuptake, 444
Dopamine, 135, 295, 422, 431, 456, 716, 756
Dopaminergic neuron firing rate, 311
Dorsolateral prefrontal cortex, 546
DRD2 Ser311Cys, 794
DRD3 Ser9Gly, 794
Drug abuse, 422
Drug addiction, 183
Drug dependence, 115
Drug discrimination, 552
Drug self-administration, 18

Drug-seeking, 18, 422

E

Eating disorder, 789
EEG spectral effects, 246
EEG, 27, 348
Electrophysiology, 164
Emotionality, 729
Epidemiology, 479
Event-related potentials, 27
Evoked potentials, 505

F

Factor analysis, 530
Factor structure, 537
False suffocation alarm hypothesis, 824
Fatigue, 643
Fluoxetine, 565
Forced swim assay, 744
Forced swimming test, 615

G

GABA-A receptor β_3 subunit, 415
Gene expression, 415
General motor activity, 737
Genetics, 692, 789
Glucocorticoid receptor, 605
Glutamate receptors, 1
Glutamate, 301, 348, 368, 456, 737
G-protein, 468
[35 S]GTPgammaS, 565
Guessing, 682

H

HAB, 94
Hallucinogen, 634
Haloperidol, 397, 595, 765
Hearing, 135
Heroin, 18
High-intensity lesions, 229
Hippocampus, 259
HPA axis, 778
5-HT_{1A} receptor, 565
5-HT_{1A} serotonin receptor, 468
5-HT_{1B} receptors, 40
5-HT_{1B}, 115
5-HT₂ receptor, 387
5-HT_{2A} receptors, 40, 311, 552
5-HT_{2C} receptor, 789
5-HT_{2C} receptors, 40
5-HT_{2C/2B} receptors, 311
HTR1B, 115
Human brain, 468
Humans, 246, 520
Hydrocortisone, 505
5-hydroxytryptophan, 340
6-Hydroxydopamine, 625, 756

I

Imaging, 802
 Immediate-early genes, 259, 275
 Immobilization, 155
 Immune challenge, 204
 Implant, 817
 Impulsivity, 716
 In vivo microdialysis, 716
 Inducible nitric oxide synthase, 155
 Informed decision, 682
 Infralimbic, 275
 Inhibitory control, 183
 Interleukin-4, 86
 Interoceptive, 552
 Intramuscular injections, 494

L

Laboratory task, 520
 Lamotrigine, 415
 Late-life depression, 229
 Latent inhibition, 765
 Learning and memory, 259
 Learning, 520
 Lipopolysaccharide, 86
 Lithium, 530
 Locomotion, 64
 Locomotor activity, 737
 Lorazepam, 494, 546
 LSD, 634
 LY235959, 301

M

M100907, 40
 Macaque, 431
 Magnetic resonance imaging, 229
 Magnetic resonance spectroscopy, 546
 Major depression, 229, 489
 Mania, 530
 MARCKS, 216
 Marijuana, 520, 802
 Maternal separation, 574
 MDL 100907, 40
 MDMA, 40, 387
 Medial forebrain bundle, 756
 Medial prefrontal cortex, 325
 Medium spiny neurons, 164
 Melanoma, 643
 Memory, 358, 505
 Methamphetamine, 130
 3,4-Methylenedioxymethamphetamine, 40
 Methylphenidate, 130
 Microdialysis, 311, 340, 583, 595
 Mixed state, 530
 ((+)-MK-801), 456
 Monoamine oxidase inhibitor, 237
 Mood disorder, 368
 Mood stabilizer, 368
 Morphine, 311
 Motor hyperactivity, 625
 Mouse, 615
 [³H]MPPF
 MRNA, 634
 Multivariate pattern recognition, 27

N

Naloxone, 106
 6-β-naltrexol, 778

Naltrexone, 778
 Neonatal lesions, 625
 Neonatal rat, 301
 Neurochemistry, 191
 Neuroendocrine, 106, 358
 Neuroimaging, 682
 Neuropeptide Y, 615
 Neuropeptide, 176
 Neurotensin receptor antagonist, 64
 Neurotensin, 64, 595
 Neurotoxicity, 387, 643
 NF-κB/Iκ-B, 397
 Nicotine, 75
 NMDA receptor antagonist, 301
 NMDA, 348
 Norepinephrine, 489
 NPY Y₁ receptors, 615
 NPY Y₂ receptors, 615
 Nuclear factor-κB, 155
 Nuclear magnetic resonance, 546
 Nucleus accumbens, 325

O

Occasion-setting, 703
 6-OHDA, 164
 8-OH-DPAT, 565
 Olanzapine, 494, 583
 Ontogeny, 301
 Opiate withdrawal, 301
 Opioid antagonist, 778
 Opioid receptor, 106
 μ-opioid receptor, 468
 Orbital frontal cortex, 682
 Orbitofrontal cortex, 183

P

P53, 397
 Panic attack, 824
 PANSS, 494
 Paraventricular nucleus, 94
 Parkinson's disease, 756
 Parkinsonism, 176
 Paroxetine, 643
 Path analysis, 229
 p-chlorophenylalanine, 340
 Perinatal alcohol, 191
 Personality, 431
 Pharmacodynamics, 27
 Phencyclidine, 130
 PHVA, 794
 Phystostigmine, 672
 PKC, 216
 Placebo, 530
 Platelet, 216
 PLC, 216
 Plus maze, 574
 Polymorphisms, 106, 115, 489, 789, 794
 Population genetics, 115
 Positron emission tomography (PET), 295, 376, 802
 Postmortem interval, 143
 Prefrontal cortex, 75, 634
 Prelimbic, 275
 Prepulse inhibition, 204, 340
 Primary cultured rat hippocampus cells, 415
 Prolactin, 135, 358, 653
 Proline endopeptidase, 176
 Promoter, 489
 Psychiatry, 546
 Psychopharmacology, 546
 Psychostimulants, 164
 Punishment, 682

Q

Quantitative autoradiography, 565

R

[¹²³I]R91150
 Raclopride, 295
 Randomized clinical trial, 530
 Rat brain, 595
 Rat, 86, 204, 286, 574
 Reaction time, 756
 Read rebreathing test, 824
 Rearing, 737
 Reinforcement, 520
 Reinstatement, 422
 Relapse, 18, 422
 Retest reliability, 269
 Reward, 130, 444, 682
 Risk, 479
 Risperidone, 595

S

SB 206553, 40
 Schizophrenia, 75, 143, 204, 325, 456, 537, 583, 765, 817
 Sensitization, 64, 286
 Serotonin receptor, 115, 634
 Serotonin transporter, 692
 Serotonin, 40, 269, 340, 358, 387, 431, 653, 660, 692, 716, 789
 Sexual diergism, 672
 Sickness behavior, 643
 Sigma₁ receptor, 444
 Sleep, 246, 348
 Smoking abstinence, 75
 SNC80, 744
 Social behavior, 86
 Solution hybridization, 301
 SPECT, 387
 SSRIs, 246
 Startle reflex, 340
 Stimulus-reward learning, 183
 Stress, 135, 286, 574
 Striatum, 295, 325, 368, 756
 Stroop color word test, 75
 Substantia nigra, 1
 Suicide, 692
 Survival analysis, 479
 Symptoms, 537
 Synaptic plasticity, 259
 Syndromes, 537

T

TACE, 155
 Tardive dyskinesia, 295, 397
 Temporal changes, 18
 Tension reduction hypothesis, 729
 THC, 802
 Tinnitus, 135
 Transgenic mice, 164, 605
 Treatment, 817
 Tricyclic, 237
 Tryptohan, 660
 Tumor necrosis factor alpha, 155
 Typical and atypical antipsychotic drugs, 325

U

Unipolar illness, 216

V

Valproate, 530
Ventral tegmental area, 1
Vertigo, 135
Visuospatial working memory, 75
Voluntary ethanol self-administration, 729

W

Withdrawal, 183, 765
Women, 660, 692
Working memory, 27
Y-931, 456